X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ASTRAZENECA PHARMA Fact Sheet, ASTRAZENECA PHARMA Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA Fact Sheet   (AIDL)

Here is the latest financial fact sheet of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA quarterly results and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

ASTRAZENECA PHARMA Price History

Price Rs 1,194.6
Mkt Cap Rs m 29,864
Vol '000 3.8
P/E X 122.2
P/CF X 310.7
EPS (TTM) Rs 9.8
% ch % 0.9
No. of shares m 25.00
% ch week % 4.9
% ch 1-mth % 18.0
% ch 12-mth % 26.0
52 week H/L Rs 1,278.0/882.6
(As on May 25, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ASTRAZENECA PHARMA Financials

No. of Mths
Year Ending
12
Dec-09
15
Mar-11
12
Mar-12
12
Mar-13
12
Mar-14
5-Yr Chart
Click to enlarge
ASTRAZENECA PHARMA EQUITY SHARE DATA
High Rs1,1091,4482,4892,6491,285 
Low Rs4218021,162595634 
Sales per share (Unadj.) Rs158.7237.7212.6156.2189.6 
Earnings per share (Unadj.) Rs23.025.77.9-35.8-0.2 
Diluted earnings per shareRs23.025.77.9-35.8-0.2 
Cash flow per share (Unadj.) Rs25.529.210.8-30.93.8 
Dividends per share (Unadj.) Rs10.0010.003.5000 
Adj. dividends per shareRs10.0010.003.500.000.00 
Dividend yield (eoy) %1.30.90.200 
Book value per share (Unadj.) Rs57.871.975.739.968.6 
Adj. book value per shareRs57.871.975.739.968.6 
Shares outstanding (eoy) m25.0025.0025.0025.0025.00 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x4.84.78.610.45.1 
Avg P/E ratio x33.243.9230.8-45.3-4,712.7 
P/CF ratio (eoy) x30.038.6168.3-52.5249.6 
Price / Book Value ratio x13.215.724.140.714.0 
Dividend payout %43.439.044.300 
Avg Mkt Cap Rs m19,12528,12545,63840,55023,988 
No. of employees `0001.51.71.71.61.6 
Total wages/salary Rs m8281,5051,6191,4851,605 
Avg. sales/employee Rs Th2,710.53,485.63,175.12,458.63,040.2 
Avg. wages/employee Rs Th565.8882.7967.2934.91,029.2 
Avg. net profit/employee Rs Th393.5376.1118.1-563.8-3.3 
ASTRAZENECA PHARMA INCOME DATA
Net Sales Rs m3,9685,9435,3153,9044,740 
Other income Rs m56606310592 
Total revenues Rs m4,0246,0035,3794,0094,832 
Gross profit Rs m8911,038303-685-130 
Depreciation Rs m618873123101 
Interest Rs m10000 
Profit before tax Rs m8841,010293-703-139 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0000139 
Tax Rs m308368951935 
Profit after tax Rs m576641198-895-5 
Gross profit margin %22.417.55.7-17.5-2.7 
Effective tax rate %34.836.532.4-27.4-3.7 
Net profit margin %14.510.83.7-22.9-0.1 
ASTRAZENECA PHARMA BALANCE SHEET DATA
Current assets Rs m2,0062,1961,9461,6482,726 
Current liabilities Rs m8941,2541,5512,0592,435 
Net working cap to sales %28.015.87.4-10.56.1 
Current ratio x2.21.81.30.81.1 
Inventory Days Days3235528074 
Debtors Days Days6327222641 
Net fixed assets Rs m3035149029821,035 
Share capital Rs m5050505050 
"Free" reserves Rs m1,3951,7471,843948942 
Net worth Rs m1,4451,7971,8939981,716 
Long term debt Rs m00000 
Total assets Rs m2,3393,0873,4493,0614,156 
Interest coverage x632.4NMNMNMNM 
Debt to equity ratio x00000 
Sales to assets ratio x1.71.91.51.31.1 
Return on assets %24.720.85.7-29.2-0.1 
Return on equity %39.935.710.4-89.8-0.3 
Return on capital %61.356.215.5-70.40 
Exports to sales %4.46.86.43.85.7 
Imports to sales %5.36.37.37.16.5 
Exports (fob) Rs m176404343147270 
Imports (cif) Rs m211372388278306 
Fx inflow Rs m287474490296375 
Fx outflow Rs m568613647406470 
Net fx Rs m-282-139-157-111-96 
ASTRAZENECA PHARMA CASH FLOW
From Operations Rs m 326 645 387 -60 -8 
From Investments Rs m 22 -277 -337 -156 -146 
From Financial Activity Rs m -1,109 -291 -291 -103 862 
Net Cashflow Rs m -761 77 -240 -320 709 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

ASTRAZENECA PHARMA Raw Materials Data

ITEM Rs m % To R.M.C. % To SALES
Codeine phosphate 47.7 7.6 1.0
Others 469.6 74.8 9.7
Packaging materials 110.4 17.6 2.3

Share Holding

Indian Promoters 0.0%
Foreign collaborators 75.0%
Indian inst/Mut Fund 0.3%
FIIs 15.7%
ADR/GDR 0.0%
Free float 9.1%
Shareholders 12,856
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 'Avishkar', Off Bellary Road, Hebbal, Bangalore - 560 024
E-MAIL comp.secy@astrazeneca.com WEB www.astrazenecaindia.com
TELEPHONE (080) 6774 8000 FAX (080) 2362 2015
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Integrated Enterp., Ramana Residency, 4th Cross, Malleswaram, Bangalore-03
AUDITOR BSR & Co.
CHM: D. E. Udwadia COMP SEC: Anantha Murthy YEAR OF INC: 1900 BSE CODE: 506820 FV (Rs): 2 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   ELDER PHARMA  CIPLA  WYETH LTD  GSK PHARMA  CADILA HEALTHCARE  

Compare ASTRAZENECA PHARMA With:   ELDER PHARMA  CIPLA  WYETH LTD  GSK PHARMA  CADILA HEALTHCARE  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Up; ONGC & Tata Steel Top Gainers(Closing)

Indian share markets ended the day on a strong note. At the closing bell, the BSE Sensex finished higher by 262 points. While, the NSE Nifty finished up by 91 points.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS